Allt inom Corporate Information

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile is similar to that of previous dose groups and that plasma exposure continues to increase with higher doses.

Bridget Lacey Appointed Chief Business Officer at Nanexa

Nanexa AB is pleased to announce the appointment of Bridget Lacey as Chief Business Officer. With over 25 years of corporate and business development experience across the life sciences sector, Bridget further strengthens Nanexa’s leadership team. Bridget’s role will initially be on a part-time basis.